Table 2.
Follow-up atrial fibrillation
| Patients without atrial fibrillation (n = 354) |
Patients with atrial fibrillation (n = 22) |
p value | |
|---|---|---|---|
| Sex (male) | 190 (53.7%) | 13 (59.1%) | 0.48 |
| Age, years | 61 (IQR, 23) | 75.5 (IQR, 16) | 0.001 |
| Comorbidities | |||
| Systolic blood pressure, mmHg | 125 (IQR, 15) | 125.5 (IQR, 21) | 0.6 |
| Smoker status | 105 (29.7%) | 5 (22.7%) | 0.48 |
| Coronary artery disease | 105 (29.7%) | 11 (50%) | 0.04 |
| Heart failure | 23 (6.5%) | 2 (9.1%) | 0.63 |
| Peripheral artery disease | 41 (11.6%) | 3 (13.6%) | 0.77 |
| Diabetes mellitus | 50 (14.2%) | 9 (40.9%) | 0.001 |
| COPD | 12 (3.4%) | 1 (4.5%) | 0.77 |
| Medication | |||
| Beta-blocker | 125 (35.3%) | 17 (77.3%) | 0.001 |
| ACE inhibitor | 159 (44.9%) | 20 (90.9%) | 0.001 |
| MRA | 17 (4.8%) | 3 (13.6%) | 0.07 |
| CCB | 55 (15.5%) | 4 (18.2%) | 0.74 |
| SAPT | 101 (28.5%) | 5 (22.7%) | 0.55 |
| DAPT | 38 (10.7%) | 1 (4.5%) | 0.35 |
| OAC | 14 (3.9%) | 2 (9%) | 0.24 |
| Echocardiography | |||
| Left atrium, mm | 36 (IQR, 6) | 36.7 ± 5.1 | 0.1 |
| Ejection fraction, % | 61 (IQR, 7) | 60 (IQR, 7) | 0.93 |
| PA-TDI [ms] | 143 (IQR 23) | 161.4 (IQR 19) | < 0.001 |
| CHA2DS2-VASc score | 2 (IQR, 2) | 4 (IQR, 1) | 0.001 |
IQR interquartile range, COPD chronic obstructive pulmonary disease, ACE Angiotensin converting enzyme, MRA mineralocorticoid receptor antagonist, CCB calcium channel blocker, NYHA New York Heart Association, SAPT single antiplatelet therapy (i.e., Aspirin or Clopidogrel), DAPT dual antiplatelet therapy (Aspirin and Clopidogrel, Aspirin and Ticagrelor or Aspirin and Prasugrel), OAC oral anticoagulation therapy (Warfarin, Dabigatran or Rivaroxaban), PA-TDI P wave to A’ wave in tissue Doppler imaging